Noopept Dosage: What the Data Shows

Noopept (INN: omberacetam) is unusual among research-chemical nootropics: it has an actual studied dose. The figure people most often reference, 10-30 mg/day split into 2-3 small oral doses, overlaps the 20 mg/day (10 mg twice daily) regimen used in Russian clinical trials of patients with mild cognitive impairment. That overlap is why Noopept's community dosing is better anchored than most research chemicals — but the full 10-30 mg/day spread above the studied 20 mg/day is community- and vendor-derived, not trial-validated.

It is also a small molecule, not an injectable peptide. Noopept is the ethyl ester of N-phenylacetyl-L-prolylglycine, a dipeptide-derived compound that is orally active and sold as powder or capsules. There is no reconstitution, no bacteriostatic water, and no injection. This guide reports where each dose number comes from — the trial-derived figure, the community range, and the gap between them.

Research-context information only. Noopept is sold as a research chemical, not for human consumption, and is not approved by Western regulators. Doses, protocols, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented and what is reported, not what should be done. Consult a licensed physician for personal medical decisions.

Noopept is one of the few compounds in this category with published human data — Russian trials, mostly open-label or piracetam-comparator, in impaired populations. That data anchors the 20 mg/day figure. The wider community range and any sublingual or cycling conventions are anecdotal. This guide keeps those streams separate and labeled.

Quick Reference: Protocol

There are two distinct sources behind the numbers below, and the table keeps them separate. The 20 mg/day figure is trial-derived; the 10-30 mg/day range and the split-dosing convention are community- and vendor-reported.

New users in community sources often start near 10 mg and adjust upward. The 20 mg/day used in the Russian comparative and stroke trials (PMID 18697252, 22500312) sits squarely inside the community range, which is part of why Noopept's reported dosing is unusually consistent. Doses above 20 mg/day are anecdotal rather than trial-validated.

A note on the "1000x more potent than piracetam" claim: it refers to potency by dose — Noopept is active at tens of milligrams where piracetam is dosed in grams — not to being 1000 times more effective. It is a dosing-potency statement, not an efficacy multiplier.

Routes of Administration

Noopept is orally active, and the oral route is both the studied route and the standard community one.

• Oral (powder or capsules): The default. Oral antiamnesic activity was established in rats (Ostrovskaya et al. 2001, PMID 11782792), and the Russian human trials dosed orally. Capsules are commonly cited around 20 mg; bulk powder is also sold. Vendor SKUs and capsule sizes change — check the current listing before ordering.
• Sublingual: Some community sources describe holding the powder sublingually. No human pharmacokinetic data supports a sublingual advantage over swallowing, so this is anecdotal preference, not an established route.
• Injectable: Not applicable. Noopept is not an injectable peptide; there is no injectable form and no reconstitution.

Community sources frequently describe pairing Noopept with a choline source to manage anecdotal headache, and commonly describe cycling several weeks on followed by a break. Neither the choline pairing nor any cycling schedule is trial-defined — both are community convention.

Handling Quick Reference

Because Noopept is an orally active small molecule sold as powder or capsules, there is no bacteriostatic-water dilution table for it — that handling language belongs to injectable peptides, and Noopept is not one. There is no reconstitution step at all.

Powder is generally described as kept dry, sealed, and stored cool away from light; purity depends entirely on the supplier's certificate of analysis, with vendors commonly claiming roughly 98%+ by HPLC. The research-grade powder or capsules sold by Western vendors are distinct from any human-grade Russian pharmaceutical product — the latter is not what is sold here. It is labeled not for human consumption.

Ready to buy? Compare the verified source we track on our best Noopept sources page, or browse all coupon codes for up to 50% off.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

The dose figures here come from two different places, and it matters which is which.

The 20 mg/day figure is trial-derived. In the comparative study of Noopept versus piracetam in mild-to-moderate cognitive impairment of vascular and traumatic origin (Neznamov & Teleshova 2008, PMID 18697252), patients took Noopept 10 mg twice daily for roughly 56 days. The authors reported efficacy at least comparable to piracetam, with greater effect in some asthenic and post-concussional subgroups, plus an anxiolytic component; the treated group's MMSE rose from about 26 to 29. An open prospective stroke study (Amelin, Ilyukhina & Shmonin 2011, PMID 22500312) dosed roughly 60 patients at about 20 mg/day and reported improved cognition and "a high level of safety." A separate clinical and EEG characterization in post-traumatic and vascular MCI (Bochkarev et al. 2008, PMID 19008801) described nonspecific cortical activation alongside an anxiolytic effect.

These are real human data — which sets Noopept apart from most research nootropics — but they are small, mostly open-label or active-comparator, Russian-language, near the originating research program, and in impaired populations rather than healthy cognitive enhancement. There is a clinically studied dose; there is not a large independent placebo-controlled efficacy base, and essentially no Western RCT.

The 10-30 mg/day range is community- and vendor-derived. It overlaps the trial figure at 20 mg/day, but the spread above it — and the split-dose, sublingual, and cycling conventions — come from forums and vendor copy, not from pharmacokinetic data. Worth flagging: community "long half-life" claims are not supported. Rat pharmacokinetics show Noopept and its active metabolite cycloprolylglycine clear quickly, with a short terminal half-life (Boyko, Zherdev & Shevchenko 2018, PMID 30378564). The proposed durable effects are attributed to downstream neurotrophic signaling, not to a long-circulating parent compound — which is also the rationale community sources give for splitting the daily dose.

Noopept is registered as a medicine in Russia but is not approved by the FDA or EMA. In Western markets it is an unapproved research chemical, sold for research use only.

Stacking Protocols

The most commonly described pairing in community sources is Noopept with a choline source, framed as a way to manage the headache that some users attribute anecdotally to choline depletion. This is community observation, not trial-established causation, and there is no trial-defined stacking protocol or human safety data for any combination.

Because Noopept's own human data is thin and limited to impaired populations, layering additional unapproved research chemicals compounds the uncertainty rather than resolving it. This guide does not report specific stack doses, as none rest on documented human evidence for healthy users.

Side Effects & Safety

Side-effect reports come from two sources, both labeled below.

• Clinical (Russian trials): Generally described as well tolerated. Adverse events in the trial literature included sleep disturbance, irritability, and increased blood pressure in a minority of patients — the blood-pressure signal is worth flagging given the vascular-MCI population studied (PMID 18697252). The stroke study reported a high level of safety (PMID 22500312). These are small, open-label cohorts; incidence figures are not from large controlled trials.
• Community (anecdotal): Headache is the most frequently reported, commonly attributed to choline depletion, alongside irritability, brain fog or fatigue, dizziness, insomnia or vivid dreams, and occasional GI upset. Some sources report overstimulation or anxiety at higher doses rather than the calming effect others describe. Reports are inconsistent; some users report no side effects.
• What is not established: There is no long-term human safety database, no Western regulatory safety review, and no robust human data on interactions, pregnancy, or chronic high-dose use. Long-term safety in healthy young users — the main community population — is essentially uncharacterized.

On research integrity: no retractions, expressions of concern, or misconduct findings were identified for the Noopept literature. The principal caveat is that much of the work comes from a single Russian originating group and from open-label, Russian-language studies — a depth-and-independence limitation, not an integrity problem.